SK284811B6 - Farmaceutická formulácia a spôsob jej výroby - Google Patents

Farmaceutická formulácia a spôsob jej výroby Download PDF

Info

Publication number: SK284811B6
Authority: SK; Slovakia
Prior art keywords: pharmaceutical formulation; cyclodextrin; amino acid; omeprazole; formulation according
Prior art date: 1997-03-13

Application number

SK1209-99A

Other languages

English (en)

Slovak (sk)

Other versions

SK120999A3 (en

Inventor

Karin Klokkers

Marion Kutschera

Wilfried Fischer

Original Assignee

Hexal Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-13

Filing date

1998-03-13

Publication date

2005-12-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8226585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284811(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-03-13 Application filed by Hexal Ag filed Critical Hexal Ag

2000-09-12 Publication of SK120999A3 publication Critical patent/SK120999A3/sk

2005-12-01 Publication of SK284811B6 publication Critical patent/SK284811B6/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
238000000034 method Methods 0.000 title claims description 21
238000002360 preparation method Methods 0.000 title description 4
229920000858 Cyclodextrin Polymers 0.000 claims abstract description 48
150000001413 amino acids Chemical class 0.000 claims abstract description 29
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 17
239000004480 active ingredient Substances 0.000 claims abstract description 10
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 claims abstract 2
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 65
229960000381 omeprazole Drugs 0.000 claims description 65
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 32
235000001014 amino acid Nutrition 0.000 claims description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
239000001116 FEMA 4028 Substances 0.000 claims description 25
229960004853 betadex Drugs 0.000 claims description 25
239000000843 powder Substances 0.000 claims description 25
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 24
239000002702 enteric coating Substances 0.000 claims description 22
238000009505 enteric coating Methods 0.000 claims description 22
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 18
239000004475 Arginine Substances 0.000 claims description 17
235000009697 arginine Nutrition 0.000 claims description 17
150000001556 benzimidazoles Chemical class 0.000 claims description 15
239000008188 pellet Substances 0.000 claims description 13
239000002245 particle Substances 0.000 claims description 11
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 10
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 10
229930064664 L-arginine Natural products 0.000 claims description 10
235000014852 L-arginine Nutrition 0.000 claims description 10
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 10
238000002156 mixing Methods 0.000 claims description 10
239000004472 Lysine Substances 0.000 claims description 8
238000001035 drying Methods 0.000 claims description 8
238000009472 formulation Methods 0.000 claims description 8
239000008187 granular material Substances 0.000 claims description 7
239000010410 layer Substances 0.000 claims description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
239000002775 capsule Substances 0.000 claims description 6
235000018977 lysine Nutrition 0.000 claims description 6
229910021529 ammonia Inorganic materials 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 5
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 4
238000004108 freeze drying Methods 0.000 claims description 4
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 4
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical group [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
108010016626 Dipeptides Proteins 0.000 claims description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
229940058303 antinematodal benzimidazole derivative Drugs 0.000 claims description 3
229940080345 gamma-cyclodextrin Drugs 0.000 claims description 3
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
239000008108 microcrystalline cellulose Substances 0.000 claims description 3
238000001694 spray drying Methods 0.000 claims description 3
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 2
235000019766 L-Lysine Nutrition 0.000 claims description 2
150000003862 amino acid derivatives Chemical class 0.000 claims description 2
239000011230 binding agent Substances 0.000 claims description 2
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 2
238000001291 vacuum drying Methods 0.000 claims description 2
238000004898 kneading Methods 0.000 claims 1
238000011084 recovery Methods 0.000 claims 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 23
229940081734 cellulose acetate phthalate Drugs 0.000 description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
239000008101 lactose Substances 0.000 description 10
238000003860 storage Methods 0.000 description 10
239000000725 suspension Substances 0.000 description 9
239000000243 solution Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
230000015556 catabolic process Effects 0.000 description 6
239000011248 coating agent Substances 0.000 description 6
238000000576 coating method Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
238000006731 degradation reaction Methods 0.000 description 6
239000000047 product Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
239000012467 final product Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000000087 stabilizing effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
WHGYBXFWUBPSRW-OYBHPSSDSA-N (1S,3R,6S,8R,11S,13R,16S,18R,21S,23R,26S,28R,31S,33R,37S,39S,41S,43S,45S,47S,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol Polymers OCC1O[C@@H]2O[C@@H]3C(CO)O[C@H](O[C@@H]4C(CO)O[C@H](O[C@@H]5C(CO)O[C@H](O[C@@H]6C(CO)O[C@H](O[C@@H]7C(CO)O[C@H](O[C@@H]8C(CO)O[C@H](O[C@H]1C(O)[C@@H]2O)[C@@H](O)C8O)[C@@H](O)C7O)[C@@H](O)C6O)[C@@H](O)C5O)[C@@H](O)C4O)[C@@H](O)C3O WHGYBXFWUBPSRW-OYBHPSSDSA-N 0.000 description 2
WHGYBXFWUBPSRW-VOXAOYDDSA-N (1S,5R,6S,10R,11S,15R,16S,20R,21S,25R,26S,30R,31S,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol Polymers OC[C@H]([C@H]([C@@H]([C@H]1O)O)OC2O[C@@H]([C@@H](OC3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)OC3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)OC3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)OC3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)OC1O[C@H]1[C@H](O)[C@@H](O)C3O[C@@H]1CO WHGYBXFWUBPSRW-VOXAOYDDSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
229920003136 Eudragit® L polymer Polymers 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
150000001447 alkali salts Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
WHGYBXFWUBPSRW-UHFFFAOYSA-N beta-cyclodextrin Polymers O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO WHGYBXFWUBPSRW-UHFFFAOYSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000008139 complexing agent Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000001198 duodenum Anatomy 0.000 description 2
239000012530 fluid Substances 0.000 description 2
GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
239000000463 material Substances 0.000 description 2
239000004570 mortar (masonry) Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000011241 protective layer Substances 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
WHGYBXFWUBPSRW-FCJOHOJTSA-N β-cyclodextrin Polymers OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@@H]2O[C@@H]([C@@H](O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FCJOHOJTSA-N 0.000 description 2
WHGYBXFWUBPSRW-QBIJAQCISA-N β-cyclodextrin Polymers OC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-QBIJAQCISA-N 0.000 description 2
WHGYBXFWUBPSRW-ZKJYHCOFSA-N β-cyclodextrin Polymers OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@@H]2O[C@@H]([C@@H](O[C@@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-ZKJYHCOFSA-N 0.000 description 2
WHGYBXFWUBPSRW-FEYSZYNQSA-N β-dextrin Polymers OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)C(O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FEYSZYNQSA-N 0.000 description 2
PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 1
JNKUAFIHOWQCSY-UHFFFAOYSA-N CC1=C(C2=C(C=C1)NC(N2C)S(=O)CC3=CC=CC=N3)OC Chemical compound CC1=C(C2=C(C=C1)NC(N2C)S(=O)CC3=CC=CC=N3)OC JNKUAFIHOWQCSY-UHFFFAOYSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 1
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000003513 alkali Substances 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
230000000767 anti-ulcer Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011247 coating layer Substances 0.000 description 1
229920001688 coating polymer Polymers 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000012055 enteric layer Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000027119 gastric acid secretion Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
-1 hydroxypropyl cyclodextrin Chemical compound 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
229950007395 leminoprazole Drugs 0.000 description 1
239000000320 mechanical mixture Substances 0.000 description 1
229940063559 methacrylic acid Drugs 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
229960005019 pantoprazole Drugs 0.000 description 1
239000000049 pigment Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
235000020004 porter Nutrition 0.000 description 1
238000012545 processing Methods 0.000 description 1
YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
229960004157 rabeprazole Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000010517 secondary reaction Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012265 solid product Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000001069 triethyl citrate Substances 0.000 description 1
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
235000013769 triethyl citrate Nutrition 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Nanotechnology (AREA)
Crystallography & Structural Chemistry (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)
Plural Heterocyclic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

SK1209-99A 1997-03-13 1998-03-13 Farmaceutická formulácia a spôsob jej výroby SK284811B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP97104200		1997-03-13
PCT/EP1998/001478 WO1998040069A2 (en)	1997-03-13	1998-03-13	Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations

Publications (2)

Publication Number	Publication Date
SK120999A3 SK120999A3 (en)	2000-09-12
SK284811B6 true SK284811B6 (sk)	2005-12-01

Family

ID=8226585

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1209-99A SK284811B6 (sk)	1997-03-13	1998-03-13	Farmaceutická formulácia a spôsob jej výroby

Country Status (23)

Country	Link
US (1)	US6248758B1 (de)
JP (1)	JP4608031B2 (de)
KR (1)	KR100563764B1 (de)
CN (1)	CN1113649C (de)
AT (1)	ATE209491T1 (de)
AU (1)	AU731186B2 (de)
BR (1)	BR9808581A (de)
CA (1)	CA2282513C (de)
CZ (1)	CZ291842B6 (de)
DE (1)	DE69802688T3 (de)
DK (1)	DK0991407T4 (de)
ES (1)	ES2167891T5 (de)
HU (1)	HU225587B1 (de)
IL (1)	IL131651A0 (de)
NO (1)	NO327212B1 (de)
NZ (1)	NZ337592A (de)
PL (1)	PL191570B1 (de)
PT (1)	PT991407E (de)
SI (1)	SI0991407T2 (de)
SK (1)	SK284811B6 (de)
TR (1)	TR199902233T2 (de)
WO (1)	WO1998040069A2 (de)
ZA (1)	ZA982155B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6096340A (en)	1997-11-14	2000-08-01	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6174548B1 (en) *	1998-08-28	2001-01-16	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
JP4127740B2 (ja) *	1998-04-20	2008-07-30	エーザイ・アール・アンド・ディー・マネジメント株式会社	安定化したベンズイミダゾール系化合物含有組成物
US6733778B1 (en) *	1999-08-27	2004-05-11	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
PT1018340E (pt) *	1999-01-06	2003-12-31	Tecnimede Sociedade Tecnico Medicinal Sa	Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem
IL130602A0 (en) *	1999-06-22	2000-06-01	Dexcel Ltd	Stable benzimidazole formulation
US6245913B1 (en)	1999-06-30	2001-06-12	Wockhardt Europe Limited	Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
DE19959419A1 (de)	1999-12-09	2001-06-21	Ratiopharm Gmbh	Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
CN1322850C (zh) *	2000-06-02	2007-06-27	沈阳药科大学	盐酸尼卡地平粉针剂及其制备方法
AU2001296908A1 (en) *	2000-09-29	2002-04-08	Geneva Pharmaceuticals, Inc.	Proton pump inhibitor formulation
AUPR549901A0 (en) *	2001-06-06	2001-07-12	Vital Health Sciences Pty Ltd	Topical formulation containing tocopheryl phosphates
KR100612398B1 (ko) *	2000-11-14	2006-08-16	바이탈 헬스 사이언시즈 피티와이 리미티드	포스페이트 유도체의 착체
GB2376231A (en) *	2001-06-06	2002-12-11	Cipla Ltd	Benzimidazole-cyclodextrin inclusion complex
AU2002317053B2 (en) *	2001-07-27	2004-08-05	Vital Health Sciences Pty Ltd	Dermal therapy using phosphate derivatives of electron transfer agents
AUPR684801A0 (en) *	2001-08-06	2001-08-30	Vital Health Sciences Pty Ltd	Supplement therapy
GB2379854B (en) *	2001-09-19	2006-04-19	Walcom Animal Science	Dairy cow feed and the use thereof
BR0215102A (pt) *	2001-12-13	2004-11-03	Vital Health Sciences Pty Ltd	Transporte transdermal de compostos, formulação tópica, método para melhorar a absorção da pele, método para a terapia de reposição hormonal, uso de um ou mais derivados de fosfato de um composto hidróxi farmacêutico em um sistema de aplicação transdermal, sistema de aplicação transdermal, método para aplicação de um composto hidróxi farmacêutico a um indivìduo e para melhorar a eficácia de uma formulação
EP1467770A1 (de) *	2002-01-15	2004-10-20	ALTANA Pharma AG	Pantoprazole-cyclodextrin-einschlusskomplex
ITMI20021074A1 (it) *	2002-05-20	2003-11-20	Actimex S R L	Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US20030228363A1 (en) *	2002-06-07	2003-12-11	Patel Mahendra R.	Stabilized pharmaceutical compositons containing benzimidazole compounds
US7732474B2 (en) *	2002-08-02	2010-06-08	Ratiopharm, Gmbh	Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
AU2002950713A0 (en)	2002-08-09	2002-09-12	Vital Health Sciences Pty Ltd	Carrier
US20040028737A1 (en) *	2002-08-12	2004-02-12	Kopran Research Laboratories Limited	Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ITMI20022549A1 (it) *	2002-12-02	2004-06-03	Actimex S R L	Composizione quaternaria comprendente come sostanza attiva la propolis.
US20040109920A1 (en) *	2002-12-04	2004-06-10	Bioactives Llc	Coated carotenoid cyclodextrin complexes
BRPI0406484A (pt) *	2003-01-17	2005-12-06	Vital Health Sciences Pty Ltd	Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
WO2004066924A2 (en) *	2003-01-24	2004-08-12	Andrx Labs Llc	Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
AU2003901815A0 (en) *	2003-04-15	2003-05-01	Vital Health Sciences Pty Ltd	Phosphate derivatives
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2557354C (en)	2004-03-03	2013-05-07	Vital Health Sciences Pty Ltd.	Alkaloid formulations
KR20050105565A (ko) *	2004-04-30	2005-11-04	에스케이케미칼주식회사	저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법
WO2005112637A1 (en) *	2004-05-14	2005-12-01	Decode Chemistry, Inc.	Formulations for non-parenteral use including hydrophobic cyclodextrins
US20060058276A1 (en) *	2004-07-15	2006-03-16	Oded Friedman	Processes for the preparation and purification of rocuronium bromide
JP5198858B2 (ja) *	2004-08-03	2013-05-15	バイタルヘルスサイエンシズプロプライアタリーリミティド	腸内投与のための担体
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005008412A1 (de)	2005-02-24	2006-09-07	Ratiopharm Gmbh	Piperazinsalz des Omeprazols und dessen Enantiomere
US20090239827A1 (en) *	2005-03-03	2009-09-24	Esra Ogru	Compounds having lipid lowering properties
MX2007015949A (es)	2005-06-17	2008-03-07	Vital Health Sciences Pty Ltd	Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007070981A1 (en) *	2005-12-23	2007-06-28	Vital Health Sciences Pty Ltd	Compounds having cytokine modulating properties
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (de)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Zusammensetzungen von DPP-IV-Inhibitoren
WO2007138606A2 (en) *	2006-06-01	2007-12-06	Dexcel Pharma Technologies Ltd.	Multiple unit pharmaceutical formulation
US7840305B2 (en)	2006-06-28	2010-11-23	3M Innovative Properties Company	Abrasive articles, CMP monitoring system and method
AU2008290582B2 (en) *	2007-08-17	2014-08-14	Boehringer Ingelheim International Gmbh	Purin derivatives for use in the treatment of fab-related diseases
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US20110038933A1 (en)	2008-05-06	2011-02-17	Dexcell Ltd.	Stable benzimidazole formulation
PE20100156A1 (es) *	2008-06-03	2010-02-23	Boehringer Ingelheim Int	Tratamiento de nafld
AU2009267145A1 (en) *	2008-06-30	2010-01-07	Merck Sharp & Dohme Corp.	Solid dosage formulations of telcagepant potassium
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
MX370599B (es) *	2008-08-15	2019-12-18	Boehringer Ingelheim Int	Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
BRPI0919288A2 (pt)	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US10071030B2 (en)	2010-02-05	2018-09-11	Phosphagenics Limited	Carrier comprising non-neutralised tocopheryl phosphate
JP5806287B2 (ja)	2010-03-30	2015-11-10	フォスファジェニクスリミティド	経皮送達パッチ
WO2011138421A1 (en)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combination therapy
NZ603319A (en)	2010-06-24	2015-04-24	Boehringer Ingelheim Int	Diabetes therapy
US8383663B2 (en)	2010-07-19	2013-02-26	Supratek Pharma Inc.	Bendamustine anionic-catioinic cyclopolysaccharide compositions
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2012122586A1 (en)	2011-03-15	2012-09-20	Phosphagenics Limited	New composition
CA2841552C (en)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
CN102584633B (zh) *	2011-12-16	2013-07-03	山东大学	一种赖氨酸α-氨基的苄氧羰基高效选择性保护方法及其产品
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP3685839A1 (de)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin zur verwendung in der behandlung von albuminuria und nierenbedingten erkrankungen
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
US20170042806A1 (en)	2015-04-29	2017-02-16	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
US20190105274A1 (en) *	2015-07-13	2019-04-11	Kyowa Hakko Bio Co., Ltd.	Tablets containing arginine at high concentration
MX383940B (es)	2015-12-09	2025-03-14	Phosphagenics Ltd	Formulación farmacéutica que contiene tocol fosfato.
CN106924179B (zh) *	2015-12-29	2021-04-30	成都康弘药业集团股份有限公司	一种含有富马酸沃诺拉赞的液体制剂及其制备方法
WO2017211979A1 (en)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinations of linagliptin and metformin
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
KR101829685B1 (ko) *	2016-07-28	2018-02-19	씨제이헬스케어 주식회사	안정성 및 용해도가 개선된 주사용 조성물
KR101829705B1 (ko) *	2016-09-21	2018-02-19	씨제이헬스케어 주식회사	안정성이 향상된 주사용 조성물
JP7198754B2 (ja)	2016-12-21	2023-01-04	アベーチョバイオテクノロジーリミテッド	方法
CN108324957B (zh) *	2018-04-20	2021-04-13	广州白云山医药集团股份有限公司白云山制药总厂	一种s-羧甲基-l-半胱氨酸包合物及其肠溶制剂组合物
CN116585283B (zh) *	2023-05-26	2024-11-22	桂林华信制药有限公司	兰索拉唑肠溶胶囊及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3427787A1 (de) *	1984-07-27	1986-01-30	Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz	Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
DE3427786A1 (de) *	1984-07-27	1986-01-30	Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz	Inklusionskomplexe von benzimidazolderivaten mit cyclodextrinen, deren herstellung und arzneimittel
US5433959A (en) *	1986-02-13	1995-07-18	Takeda Chemical Industries, Ltd.	Stabilized pharmaceutical composition
KR920008161B1 (ko) *	1990-02-19	1992-09-24	한미약품공업주식회사	오메프라졸 경구용 약제의 제조방법
KR930000861B1 (ko) *	1990-02-27	1993-02-08	한미약품공업 주식회사	오메프라졸 직장투여 조성물
US5232706A (en) *	1990-12-31	1993-08-03	Esteve Quimica, S.A.	Oral pharmaceutical preparation containing omeprazol
JPH05194225A (ja) *	1991-11-07	1993-08-03	Yoshitomi Pharmaceut Ind Ltd	安定化された抗潰瘍剤含有製剤
TW224049B (de) *	1991-12-31	1994-05-21	Sunkyong Ind Ltd
AU4513393A (en) *	1992-07-17	1994-02-14	Astra Aktiebolag	Pharmaceutical composition containing antiulcer agent
CZ289804B6 (cs) *	1994-07-08	2002-04-17	Astrazeneca Ab	Multijednotková tabletovaná dávková forma I
SE9500478D0 (sv) *	1995-02-09	1995-02-09	Astra Ab	New pharmaceutical formulation and process
AU5780696A (en) *	1995-06-02	1996-12-18	Takeda Chemical Industries Ltd.	Stabilized composition comprising an antiulcerative benzimid azole
JPH0948730A (ja) *	1995-06-02	1997-02-18	Takeda Chem Ind Ltd	水溶性の改善されたベンズイミダゾール系抗潰瘍剤含有安定組成物

1998
- 1998-03-13 CZ CZ19993128A patent/CZ291842B6/cs not_active IP Right Cessation
- 1998-03-13 IL IL13165198A patent/IL131651A0/xx not_active IP Right Cessation
- 1998-03-13 HU HU0002364A patent/HU225587B1/hu not_active IP Right Cessation
- 1998-03-13 AT AT98919099T patent/ATE209491T1/de active
- 1998-03-13 KR KR1019997008327A patent/KR100563764B1/ko not_active Expired - Fee Related
- 1998-03-13 WO PCT/EP1998/001478 patent/WO1998040069A2/en not_active Ceased
- 1998-03-13 PL PL335571A patent/PL191570B1/pl unknown
- 1998-03-13 SK SK1209-99A patent/SK284811B6/sk not_active IP Right Cessation
- 1998-03-13 PT PT98919099T patent/PT991407E/pt unknown
- 1998-03-13 TR TR1999/02233T patent/TR199902233T2/xx unknown
- 1998-03-13 CA CA002282513A patent/CA2282513C/en not_active Expired - Fee Related
- 1998-03-13 BR BR9808581-6A patent/BR9808581A/pt not_active Application Discontinuation
- 1998-03-13 DK DK98919099T patent/DK0991407T4/da active
- 1998-03-13 CN CN98803296A patent/CN1113649C/zh not_active Expired - Fee Related
- 1998-03-13 SI SI9830069T patent/SI0991407T2/xx unknown
- 1998-03-13 US US09/319,895 patent/US6248758B1/en not_active Expired - Lifetime
- 1998-03-13 ES ES98919099T patent/ES2167891T5/es not_active Expired - Lifetime
- 1998-03-13 AU AU72070/98A patent/AU731186B2/en not_active Ceased
- 1998-03-13 NZ NZ337592A patent/NZ337592A/xx not_active IP Right Cessation
- 1998-03-13 JP JP53923798A patent/JP4608031B2/ja not_active Expired - Fee Related
- 1998-03-13 ZA ZA982155A patent/ZA982155B/xx unknown
- 1998-03-13 DE DE69802688T patent/DE69802688T3/de not_active Expired - Lifetime
1999
- 1999-09-10 NO NO19994409A patent/NO327212B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO1998040069A3 (en)	1998-12-17
SK120999A3 (en)	2000-09-12
HUP0002364A3 (en)	2001-12-28
WO1998040069A2 (en)	1998-09-17
KR20000076232A (ko)	2000-12-26
HUP0002364A2 (hu)	2000-12-28
JP2001518083A (ja)	2001-10-09
SI0991407T2 (en)	2005-10-31
CZ291842B6 (cs)	2003-06-18
ZA982155B (en)	1998-12-01
CZ312899A3 (cs)	2000-02-16
DK0991407T3 (da)	2002-03-25
SI0991407T1 (en)	2002-04-30
HK1024182A1 (en)	2000-10-05
HU225587B1 (en)	2007-03-28
CA2282513A1 (en)	1998-09-17
PL191570B1 (pl)	2006-06-30
TR199902233T2 (xx)	1999-12-21
DE69802688D1 (de)	2002-01-10
NO994409D0 (no)	1999-09-10
AU7207098A (en)	1998-09-29
PL335571A1 (en)	2000-05-08
US6248758B1 (en)	2001-06-19
ATE209491T1 (de)	2001-12-15
DE69802688T3 (de)	2006-01-26
KR100563764B1 (ko)	2006-03-24
DK0991407T4 (da)	2005-08-08
ES2167891T3 (es)	2002-05-16
AU731186B2 (en)	2001-03-29
CN1250372A (zh)	2000-04-12
EP0991407A2 (de)	2000-04-12
DE69802688T2 (de)	2002-08-01
ES2167891T5 (es)	2005-11-16
NO994409L (no)	1999-10-21
NZ337592A (en)	2001-01-26
NO327212B1 (no)	2009-05-11
JP4608031B2 (ja)	2011-01-05
EP0991407B9 (de)	2002-11-13
IL131651A0 (en)	2001-01-28
EP0991407B1 (de)	2001-11-28
CN1113649C (zh)	2003-07-09
PT991407E (pt)	2002-05-31
CA2282513C (en)	2007-09-18
BR9808581A (pt)	2000-05-30

Legal Events

Date	Code	Title	Description
2017-12-04	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20170313

Publication	Publication Date	Title
SK120999A3 (en)	2000-09-12	STABILIZATION OF ACID SENSITIVE BENZIMIDAZOLES WITH AMINOì (54) ACID/CYCLODEXTRIN COMBINATIONS
EP2645996B1 (de)	2016-03-02	Verfahren zur herstellung einer ppi-haltigen pharmazeutischen zubereitung
US6207198B1 (en)	2001-03-27	Composition containing an acid-labile omeprazole and process for its preparation
CZ316594A3 (en)	1995-05-17	Stomach protecting stable omeprazole preparations having the form of micro-capsules and process for preparing thereof
SK284892B6 (sk)	2006-02-02	Orálny farmaceutický prostriedok obsahujúci zlúčeninu s protivredovou aktivitou a spôsob jeho prípravy
HU203200B (en)	1991-06-28	Process for producing oral pharmaceutical compositions comprising acid-sensitive benzimidazole derivatives
US5362860A (en)	1994-11-08	Neutral stabilization complex for CI-979 HCl, a cognition activator
EP0797441B1 (de)	2002-02-27	Lamotrigin haltiges arzneimittel
CZ292290B6 (cs)	2003-08-13	Částice potažené granulovaným krystalickým ibuprofenem
EP1018340B1 (de)	2003-09-10	Cyclodextrin Einschlusskomplexe mit Aminosäuresalzen von Benzimidazolderivaten, deren Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen
EP2345408A2 (de)	2011-07-20	Säurelabile Arzneimittelformulierungen
EP0991407B2 (de)	2005-06-01	Stabilisierung von säureempfindluchen benzimidazolen unter verwendung von aminosäure/cyclodextrin kombinationen
MXPA99008374A (en)	2000-02-02	Stabilization of acid sensitive benzimidazols with amino/cyclodextrin combinations
RU2161481C2 (ru)	2001-01-10	Новая композиция, содержащая кислотно-нестойкий омепразол, и способ ее получения
JPWO2004089344A1 (ja)	2006-07-06	錠剤の製造方法
KR20210102717A (ko)	2021-08-20	아픽사반 또는 그 약리상 허용되는 염을 포함하는 약제학적 조성물, 이를 이용한 아픽사반 제제 및 이의 제조 방법
KR100502505B1 (ko)	2005-07-20	오메프라졸 경구제제의 제조방법
SK277827B6 (en)	1995-04-12	Method of production of solid pharmaceutical agent